Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

Clicks: 280
ID: 119667
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #7 of 7 articles by views in journal of ophthalmology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, …
Reference Key
s2013journalvisual Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sabour-Pickett S;Loughman J;Nolan JM;Stack J;Pesudovs K;Meagher KA;Beatty S;;
Journal journal of ophthalmology
Year 2013
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/23533703
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:23533703 pmc3595676 doi:10.1155/2013/268438 sarah sabour-pickett james loughman stephen beatty

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.